循环肿瘤DNA中PIK3CA突变状态可预测Buparlisib联用氟维司群在部分应用芳香化酶抑制剂乳腺癌患者的疗效

    PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib (BUP) Plus Fulvestrant (FULV) in Breast Cancer Patient with Aromatase Inhibitors

    • Abstract: Conclusion

       

    /

    返回文章
    返回